Shareholding
HASH(0x875e078)
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii" />
<title></title>
<meta content="HTML Tidy for Windows (vers 21 March 2007), see www.w3.org" name="generator" />
<style type="text/css">
/*<![CDATA[*/
/**/
/**/
/**/
/**/
body.c12 {margin-right:90pt;margin-left:90pt;margin-top:72pt;margin-bottom:72pt;font-family:Times New Roman}
td.c11 {padding-top:0pt;padding-left:0pt;padding-bottom:0pt;padding-right:0pt;width:0pt}
p.c10 {margin-top:5pt;margin-bottom:5pt;padding-top:0pt;padding-bottom:0pt;font-size:12pt;text-align:justify}
p.c9 {margin-top:0pt;margin-bottom:0pt;padding-top:0pt;padding-bottom:0pt;font-size:12pt;text-align:justify}
p.c8 {margin-top:0pt;margin-bottom:0pt;padding-top:0pt;padding-bottom:0pt;font-size:12pt;text-align:center}
span.c7 {font-family:Arial;font-weight:bold;font-size:10pt;}
p.c6 {margin:0;padding:0;}
table.c5 {border-collapse:collapse;}
p.c4 {margin-top:0pt;margin-bottom:0pt;padding-top:0pt;padding-bottom:0pt;font-size:12pt;text-align:right}
td.c3 {padding-top:0pt;padding-left:5.4pt;padding-bottom:0pt;padding-right:5.4pt;width:221.4pt}
p.c2 {margin-top:0pt;margin-bottom:0pt;padding-top:0pt;padding-bottom:0pt;font-size:12pt;text-align:left}
span.c1 {font-family:Arial;font-size:10pt;}
/**/
/**/
/**/
/**/
/*]]>*/
</style>
</head>
<body class="c12"><div>RNS Number : 9542Z</div> <div>Proximagen Neuroscience Plc</div> <div>25 July 2008</div> <div> </div>
<p></p>
<table class="c5 FCK__ShowTableBorders" cellspacing="0" cellpadding="0" summary="summary info">
<tbody>
<tr>
<td class="c3" valign="top">
<p class="c2"><span class="c1">For immediate release</span></p>
</td>
<td class="c3" valign="top">
<p class="c4"><span class="c1">25 July 2008</span></p>
</td>
</tr>
</tbody>
</table>
<p class="c6"><br /></p>
<p class="c6"><br /></p>
<p class="c6"><br /></p>
<p class="c8"><span class="c7">Proximagen Neuroscience plc </span></p>
<p class="c6"><br /></p>
<p class="c8"><span class="c7">('the Company')</span></p>
<p class="c6"><br /></p>
<p class="c8"><span class="c7">Declaration of Major Shareholding</span></p>
<p class="c6"><br /></p>
<p class="c6"><br /></p>
<p class="c9"><span class="c1">The Company was notified on </span><span class="c1">25 July 2008</span><span class="c1"> that</span><span class="c1"> </span><span class="c1">as of 17 July 2008, </span><span class="c1">New Star Asset Management Limited has an interest in </span><span class="c1">942,430</span><span class="c1"> </span><span class="c1">ordinary shares of 1p each</span><span class="c1"> in the Company ("Ordinary Shares")</span><span class="c1">, representing </span><span class="c1">4.7</span><span class="c1">% of the </span><span class="c1">entire </span><span class="c1">issued share capital of the Company</span><span class="c1">, being </span><span class="c1">20,058,872</span><span class="c1"> Ordinary Shares</span><span class="c1">.  </span></p>
<p class="c6"><br /></p>
<p class="c6"><br /></p>
<p class="c10"><span class="c1">For further information, please contact: </span></p>
<table class="c5 FCK__ShowTableBorders" cellspacing="0" cellpadding="0" summary="summary info">
<tbody>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Proximagen Neuroscience plc</span></p>
</td>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Tel: 020 7848 6938</span></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Kenneth Mulvany, Chief Executive  </span></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">James Hunter, Finance Director</span></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Buchanan Communications</span></p>
</td>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Tel: 020 7466 5000</span></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Mary-Jane Johnson, Tim Anderson, Catherine Breen </span></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Canaccord Adams Limited (NOMAD)</span></p>
</td>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Tel: 020 7050 6500</span></p>
</td>
</tr>
<tr>
<td class="c11" valign="top">
<p class="c10"><span class="c1">Mark Williams, Adria Da Breo-Richards</span></p>
</td>
<td class="c11" valign="top">
<p class="c6"><br /></p>
</td>
</tr>
</tbody>
</table>
<p class="c6"><br /></p>
<p class="c10"><span class="c1">About Proximagen</span></p>
<p class="c10"><span class="c1">Proximagen is a drug discovery and development company that is primarily focused on the identification and subsequent out-licensing of novel therapeutics to improve the quality of life for patients suffering from neurodegenerative disease such as Parkinson's disease and Alzheimer's disease.</span></p>
<p class="c10"><span class="c1">Proximagen is building a development pipeline to address the significant medical needs of these patients and has made substantial progress in five proprietary programmes. Proximagen anticipates out-licensing its programmes at early stages up to and including Phase II proof of concept studies and commercialising carefully selected in-licensed and collaborative programmes.</span></p>
<p class="c10"><span class="c1">Proximagen joined the AIM market of the London Stock Exchange in March 2005. For more information please visit the Company's web site: www.proximagen.com.</span></p>
<p class="c6"><br /></p>
<div style="text-align:center;"><br/>This information is provided by RNS</div><div style="text-align:center;">The company news service from the London Stock Exchange</div><div> </div> END<div> </div><div> </div>HOLFKPKBABKDDOB</body>
</html>
|
